for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alkermes schizophrenia drug gets U.S. FDA nod

June 1 (Reuters) - Alkermes Plc said on Tuesday the U.S. Food and Drug Administration (FDA) approved its drug Lybalvi to treat schizophrenia and bipolar I disorder.

The company expects to commercially launch the drug in the fourth quarter. (Reporting by Dania Nadeem in Bengaluru; Editing by Aditya Soni)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up